Tarsus Pharmaceuticals Inc
TARS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.19B
Close$
$-40.00
158.6% downside
Current Fair Value
158.6% downsideOvervalued by 158.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.19 Billion |
|---|---|
| Enterprise Value | $2.99 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.59 |
| Beta | 0.54 |
| Outstanding Shares | 43,393,643 |
Return
| Return on Equity | -13.40% |
|---|---|
| Return on Assets | -7.60% |
| Return on Invested Capital | -8.83% |
Valuation & Multiples
| P/E Ratio | -62.57 |
|---|---|
| PEG | 711.37 |
| Price to Sales | 5.25 |
| Price to Book Ratio | 9.74 |
| Enterprise Value to Revenue | 4.93 |
| Enterprise Value to EBIT | -77.72 |
| Enterprise Value to Net Income | -65 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$169.65 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-1.49
Average shareholder expectationRevenue Estimate
$186.56 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 97.11% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.77%▼ 107.06% |
|---|---|
| Total Invested | $94.59M▼ 96.85% |
| Investors Holding | 15▼ 255.00% |
ESG Score
No data
About Tarsus Pharmaceuticals Inc
20 employeesTarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a num...